
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1398284/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer, 2009, 115, 5723-5733.	2.0	210
2	Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. JAMA Oncology, 2020, 6, 1397.	3.4	183
3	Novel <i>MYBL1</i> Gene Rearrangements with Recurrent <i>MYBL1–NFIB</i> Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations. Clinical Cancer Research, 2016, 22, 725-733.	3.2	167
4	International neural monitoring study group guideline 2018 part I: Staging bilateral thyroid surgery with monitoring loss of signal. Laryngoscope, 2018, 128, S1-S17.	1.1	162
5	Squamous cell carcinoma of the head and neck in never smoker–never drinkers: A descriptive epidemiologic study. Head and Neck, 2008, 30, 75-84.	0.9	161
6	Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i>BRAF^{V600E}</i> -Mutated Anaplastic Thyroid Carcinoma. Thyroid, 2019, 29, 1036-1043.	2.4	156
7	Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. , 2018, 6, 68.		148
8	Reirradiation of Head and Neck Cancers With Proton Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 96, 30-41.	0.4	123
9	Papillary Thyroid Cancer—Aggressive Variants and Impact on Management: A Narrative Review. Advances in Therapy, 2020, 37, 3112-3128.	1.3	115
10	Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid, 2017, 27, 672-681.	2.4	111
11	International neuromonitoring study group guidelines 2018: Part II: Optimal recurrent laryngeal nerve management for invasive thyroid cancer—incorporation of surgical, laryngeal, and neural electrophysiologic data. Laryngoscope, 2018, 128, S18-S27.	1.1	111
12	Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma. Thyroid, 2018, 28, 945-951.	2.4	111
13	Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1117-1131.	0.4	100
14	Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions. Thyroid, 2018, 28, 1301-1310.	2.4	96
15	Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma. Thyroid, 2018, 28, 79-87.	2.4	91
16	Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3698-3705.	1.8	91
17	Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus. Oral Oncology, 2016, 56, 47-53.	0.8	88
18	Esthesioneuroblastoma: 25â€year experience at a single institution. Otolaryngology - Head and Neck Surgery, 2008, 138, 452-458.	1.1	87

#	Article	IF	CITATIONS
19	Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. Journal of Oncology Practice, 2016, 12, 511-518.	2.5	81
20	Depth of invasion as a predictor of nodal disease and survival in patients with oral tongue squamous cell carcinoma. Head and Neck, 2019, 41, 177-184.	0.9	79
21	Complications, hospital length of stay, and readmission after total laryngectomy. Cancer, 2017, 123, 1760-1767.	2.0	72
22	Acquired Secondary RAS Mutation in BRAF ^{V600E} -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid, 2020, 30, 1288-1296.	2.4	66
23	Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid, 2018, 28, 982-990.	2.4	62
24	Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer, 2013, 119, 2593-2601.	2.0	61
25	Supraglottoplasty for Laryngomalacia With Obstructive Sleep Apnea. Laryngoscope, 2008, 118, 1873-1877.	1.1	60
26	Surgical management of the recurrent laryngeal nerve in thyroidectomy: American Head and Neck Society Consensus Statement. Head and Neck, 2018, 40, 663-675.	0.9	58
27	Facial nerve electrodiagnostics for patients with facial palsy: a clinical practice guideline. European Archives of Oto-Rhino-Laryngology, 2020, 277, 1855-1874.	0.8	58
28	Parathyroid cancer: An update. Cancer Treatment Reviews, 2020, 86, 102012.	3.4	58
29	Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. Critical Reviews in Oncology/Hematology, 2019, 137, 84-91.	2.0	55
30	Matched-Pair Analysis of Race or Ethnicity in Outcomes of Head and Neck Cancer Patients Receiving Similar Multidisciplinary Care. Cancer Prevention Research, 2009, 2, 782-791.	0.7	51
31	Thyroid Disease Around the World. Otolaryngologic Clinics of North America, 2018, 51, 631-642.	0.5	51
32	Salvage total laryngectomy after externalâ€beam radiotherapy: A 20â€year experience. Head and Neck, 2016, 38, E1962-8.	0.9	50
33	American Head and Neck Society Endocrine Surgery Section update on parathyroid imaging for surgical candidates with primary hyperparathyroidism. Head and Neck, 2019, 41, 2398-2409.	0.9	50
34	Surgical Salvage of Recurrent Cancer of the Head and Neck. Current Oncology Reports, 2014, 16, 386.	1.8	49
35	Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2018, 144, 108.	1.2	49
36	Low risk of second primary malignancies among never smokers with human papillomavirus–associated index oropharyngeal cancers. Head and Neck, 2013, 35, 794-799.	0.9	46

#	Article	IF	CITATIONS
37	Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Annals of Surgical Oncology, 2018, 25, 3380-3388.	0.7	46
38	Intraoperative opioids use for laryngeal squamous cell carcinoma surgery and recurrence: a retrospective study. Journal of Clinical Anesthesia, 2015, 27, 672-679.	0.7	43
39	Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head and Neck, 2021, 43, E7-E12.	0.9	42
40	Distant Metastases From Childhood Differentiated Thyroid Carcinoma: Clinical Course and Mutational Landscape. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1683-1697.	1.8	42
41	Complications and functional outcomes following complex oropharyngeal reconstruction. Head and Neck, 2010, 32, 1003-1011.	0.9	41
42	American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment. Head and Neck, 2022, 44, 1277-1300.	0.9	41
43	Neighborhood deprivation and clinical outcomes among head and neck cancer patients. Health and Place, 2012, 18, 861-868.	1.5	40
44	Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1244.	1.2	39
45	Influence of timing, radiation, and reconstruction on complications and speech outcomes with tracheoesophageal puncture. Head and Neck, 2016, 38, 1765-1771.	0.9	38
46	Head and neck surgical oncology in the time of a pandemic: Subsiteâ€specific triage guidelines during the <scp>COVID</scp> â€19 pandemic. Head and Neck, 2020, 42, 1194-1201.	0.9	38
47	Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2198-2207.	1.8	37
48	Update of Radiofrequency Ablation for Treating Benign and Malignant Thyroid Nodules. The Future Is Now. Frontiers in Endocrinology, 2021, 12, 698689.	1.5	37
49	Effect of Initial Treatment on Disease Outcome for Patients With Submandibular Gland Carcinoma. JAMA Otolaryngology, 2007, 133, 546.	1.5	36
50	Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmologica, 2017, 95, e323-e328.	0.6	36
51	Longâ€ŧerm outcomes after multidisciplinary management of T3 laryngeal squamous cell carcinomas: Improved functional outcomes and survival with modern therapeutic approaches. Head and Neck, 2016, 38, 1739-1751.	0.9	33
52	Genetic profiling as a clinical tool in advanced parathyroid carcinoma. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1977-1986.	1.2	30
53	Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head and Neck, 2020, 42, 1325-1328.	0.9	29
54	Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer. Frontiers in Endocrinology, 2021, 12, 720723.	1.5	29

#	Article	IF	CITATIONS
55	Conditional Survival Analysis of Patients With Locally Advanced Laryngeal Cancer: Construction of a Dynamic Risk Model and Clinical Nomogram. Scientific Reports, 2017, 7, 43928.	1.6	28
56	Imaging of Anaplastic Thyroid Carcinoma. American Journal of Neuroradiology, 2018, 39, 547-551.	1.2	27
57	Risks of Hypoparathyroidism After Total Thyroidectomy in Children: A 21â€Year Experience in a Highâ€Volume Cancer Center. World Journal of Surgery, 2020, 44, 442-451.	0.8	27
58	Management of the lateral neck compartment in patients with sporadic medullary thyroid cancer. Head and Neck, 2018, 40, 79-85.	0.9	25
59	Prognostic performance of the American Joint Committee on Cancer 8th edition of the TNM staging system in patients with early oral tongue cancer. Head and Neck, 2019, 41, 1270-1276.	0.9	25
60	Outcomes of carotidâ€sparing IMRT for T1 glottic cancer: Comparison with conventional radiation. Laryngoscope, 2020, 130, 146-153.	1.1	25
61	Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC) Journal of Clinical Oncology, 2020, 38, 6514-6514.	0.8	25
62	Head and neck surgical subspecialty training in Africa: Sustainable models to improve cancer care in developing countries. Head and Neck, 2017, 39, 605-611.	0.9	24
63	Decision making for the central compartment in differentiated thyroid cancer. European Journal of Surgical Oncology, 2018, 44, 1671-1678.	0.5	24
64	Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis, 2009, 30, 997-1002.	1.3	23
65	Management of the Neck in Well-Differentiated Thyroid Cancer. Current Oncology Reports, 2021, 23, 1.	1.8	22
66	Immediate Intraoperative Repair of the Recurrent Laryngeal Nerve in Thyroid Surgery. Laryngoscope, 2021, 131, 1429-1435.	1.1	22
67	Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma. Thyroid, 2021, 31, 1235-1243.	2.4	22
68	<i>FAS</i> and <i>FASLG</i> Genetic Variants and Risk for Second Primary Malignancy in Patients with Squamous Cell Carcinoma of the Head and Neck. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1484-1491.	1.1	21
69	<i>p14ARF</i> genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Cancer, 2011, 117, 1227-1235.	2.0	21
70	Head and neck inflammatory pseudotumor: Case series and review of the literature. Neuroradiology Journal, 2016, 29, 440-446.	0.6	20
71	Ageâ€adjusted comorbidity and survival in locally advanced laryngeal cancer. Head and Neck, 2018, 40, 2060-2069.	0.9	20
72	Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. Journal of the National Cancer Institute, 2017, 109, .	3.0	19

#	Article	lF	CITATIONS
73	Glutathione <i>S</i> -Transferase Polymorphisms and Risk of Second Primary Malignancy after Index Squamous Cell Carcinoma of the Head and Neck. Cancer Prevention Research, 2009, 2, 432-439.	0.7	18
74	Section for Residents and Fellowsâ€inâ€Training Survey Results. Otolaryngology - Head and Neck Surgery, 2013, 148, 582-588.	1.1	18
75	Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head and Neck, 2017, 39, 1609-1620.	0.9	18
76	Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000Research, 2018, 7, 87.	0.8	18
77	Long-Term Outcomes of Lateral Neck Dissection in Patients with Recurrent or Persistent Well-Differentiated Thyroid Cancer. Thyroid, 2017, 27, 1291-1299.	2.4	17
78	Evaluation and Staging of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx. Otolaryngologic Clinics of North America, 2013, 46, 599-613.	0.5	16
79	Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. Head and Neck, 2017, 39, 633-638.	0.9	16
80	A prospective in silico analysis of interdisciplinary and interobserver spatial variability in post-operative target delineation of high-risk oral cavity cancers: Does physician specialty matter?. Clinical and Translational Radiation Oncology, 2018, 12, 40-46.	0.9	16
81	Clinical outcomes after local field conformal reirradiation of patients with retropharyngeal nodal metastasis. Head and Neck, 2017, 39, 2079-2087.	0.9	15
82	Postoperative local-regional radiation therapy in the treatment of parathyroid carcinoma: The MD Anderson experience of 35 years. Practical Radiation Oncology, 2017, 7, e463-e470.	1.1	15
83	African Head and Neck Society Clinical Practice guidelines for thyroid nodules and cancer in developing countries and limited resource settings. Head and Neck, 2020, 42, 1746-1756.	0.9	15
84	ACR Appropriateness Criteria® Parathyroid Adenoma. Journal of the American College of Radiology, 2021, 18, S406-S422.	0.9	15
85	Anaplastic Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2022, 51, 391-401.	1.2	15
86	Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis, 2010, 31, 222-227.	1.3	14
87	Educational workshops with graduates of the University of Cape Town Karl Storz Head and Neck Surgery Fellowship Program: a model for collaboration in outreach to developing countries. SpringerPlus, 2016, 5, 1652.	1.2	14
88	Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: Quantitative image analysis of post-radiotherapy response. Oral Oncology, 2015, 51, 195-201.	0.8	13
89	Chronic Retropharyngeal Abscess Presenting as Obstructive Sleep Apnea. Pediatric Emergency Care, 2008, 24, 382-384.	0.5	12
90	<i>p73</i> G4C14â€ŧoâ€A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. International Journal of Cancer, 2009, 125, 2660-2665.	2.3	12

#	Article	IF	CITATIONS
91	Genetic variants of the <i>p53</i> and <i>p73</i> genes jointly increase risk of second primary malignancies in patients after index squamous cell carcinoma of the head and neck. Cancer, 2012, 118, 485-492.	2.0	12
92	Prevalence and Risk Factors for Multifocality in Pediatric Thyroid Cancer. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 1100.	1.2	12
93	Evaluating the Rising Incidence of Thyroid Cancer and Thyroid Nodule Detection Modes. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 811.	1.2	12
94	Association of <i>p53</i> codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck. Cancer, 2010, 116, 2350-2359.	2.0	11
95	Primary Malignant Thyroid Teratoma: An Institutional Experience. Thyroid, 2019, 29, 229-236.	2.4	11
96	A Thyroid Genetic Classifier Correctly Predicts Benign Nodules with Indeterminate Cytology: Two Independent, Multicenter, Prospective Validation Trials. Thyroid, 2020, 30, 704-712.	2.4	11
97	Case for staged thyroidectomy. Head and Neck, 2020, 42, 3061-3071.	0.9	11
98	Association between postoperative complications and longâ€ŧerm oncologic outcomes following total laryngectomy: 10â€year experience at MD Anderson Cancer Center. Cancer, 2020, 126, 4905-4916.	2.0	10
99	A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2962-2978.	1.8	10
100	Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis. Advances in Therapy, 2021, 38, 5144-5164.	1.3	10
101	<i>TNFâ€Î±</i> promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx. International Journal of Cancer, 2014, 135, 1615-1624.	2.3	9
102	Oral cavity cancer management guidelines for lowâ€resource regions. Head and Neck, 2019, 41, 799-812.	0.9	9
103	Association of Pharyngocutaneous Fistula With Cancer Outcomes in Patients After Laryngectomy. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 1027.	1.2	9
104	Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma. JCO Precision Oncology, 2018, 2, 1-11.	1.5	8
105	Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4652-e4665.	1.8	8
106	Transoral endoscopic vestibular approach for thyroidectomy and parathyroidectomy – From promise to practice. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2021, 42, 103022.	0.6	8
107	Trends in Diagnosis of Noninvasive Follicular Thyroid Neoplasm With Papillarylike Nuclear Features and Total Thyroidectomies for Patients With Papillary Thyroid Neoplasms. JAMA Otolaryngology - Head and Neck Surgery, 2022, 148, 99.	1.2	8
108	Revisiting the role of surgery in the treatment of Graves' disease. Clinical Endocrinology, 2022, 96, 747-757.	1.2	8

#	Article	IF	CITATIONS
109	Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?. JCO Precision Oncology, 2022, 6, e2100467.	1.5	8
110	Functional polymorphisms in the <i>insulinâ€like binding proteinâ€3</i> gene may modulate susceptibility to differentiated thyroid carcinoma in Caucasian Americans. Molecular Carcinogenesis, 2012, 51, E158-67.	1.3	7
111	The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer. Hormones and Cancer, 2019, 10, 97-106.	4.9	7
112	Current therapeutic options for lowâ€risk papillary thyroid carcinoma: Scoping evidence review. Head and Neck, 2022, 44, 226-237.	0.9	7
113	Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncology, 2018, 79, 1-8.	0.8	6
114	ASO Author Reflections: Strap Muscle Invasion Does Not Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer. Annals of Surgical Oncology, 2018, 25, 892-893.	0.7	6
115	Vascular flow on doppler sonography may not be a valid characteristic to distinguish colloid nodules from papillary thyroid carcinoma even when accounting for nodular size. Gland Surgery, 2019, 8, 461-468.	0.5	6
116	Frozen section in thyroid gland follicular neoplasms: It's high time to abandon it!. Surgical Oncology, 2021, 36, 76-81.	0.8	6
117	Primary hyperparathyroidism: Disease of diverse genetic, symptomatic, and biochemical phenotypes. Head and Neck, 2021, 43, 3996-4009.	0.9	6
118	OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1) Tj ETQ of the Endocrine Society, 2019, 3, .	q0 0 0 rgl 0.1	3T /Overlock 6
119	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The state of science in medullary thyroid carcinoma: current challenges and unmet needs. Endocrine-Related Cancer, 2020, 27, T27-T39.	1.6	6
120	Tracheal and Cricotracheal Resection With End-to-End Anastomosis for Locally Advanced Thyroid Cancer: A Systematic Review of the Literature on 656 Patients. Frontiers in Endocrinology, 2021, 12, 779999.	1.5	6
121	Segmental tracheal resection (nine rings) and reconstruction for carcinoma showing thymusâ€like differentiation (CASTLE) of the thyroid. Head and Neck, 2019, 41, 3478-3481.	0.9	5
122	Distinguishing Recurrent Thyroid Cancer from Residual Nonmalignant Thyroid Tissue Using Multiphasic Multidetector CT. American Journal of Neuroradiology, 2020, 41, 844-851.	1.2	5
123	Non-functional water clear cell parathyroid carcinoma masquerading as medullary thyroid carcinoma. Annals of Diagnostic Pathology, 2021, 54, 151791.	0.6	5
124	Thyroid Cancer and lodine Deficiency Status: A 10-Year Review at a Single Cancer Center in Tanzania. OTO Open, 2018, 2, 2473974X1877723.	0.6	4
125	Thyroid Surgery: Whose Domain Is It?. Advances in Therapy, 2019, 36, 2541-2546.	1.3	4
126	Head and neck surgery global outreach: Ethics, planning, and impact. Head and Neck, 2021, 43, 1780-1787.	0.9	4

MARK ZAFEREO, FACS

#	Article	IF	CITATIONS
127	Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2022, 51, 379-389.	1.2	4
128	Utility of subcategorization of atypia of undetermined significance/follicular lesion of undetermined significance category in ultrasound-guided thyroid fine-needle aspiration in a large referral cancer center. Journal of the American Society of Cytopathology, 2019, 8, 309-316.	0.2	3
129	Parapharyngeal Dissection for Papillary Thyroid Cancer. VideoEndocrinology, 2019, 6, .	0.1	3
130	Challenges facing otolaryngologists in low- and middle-income countries during the COVID-19 pandemic. International Journal of Pediatric Otorhinolaryngology, 2020, 138, 110322.	0.4	3
131	Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid. JMIR Formative Research, 2021, 5, e27484.	0.7	3
132	Surgical Considerations in Thyroid Cancer. Neuroimaging Clinics of North America, 2021, 31, 327-335.	0.5	3
133	Facilitating rapid precision oncology in anaplastic thyroid cancer: Clinical implications of next generation sequencing (NGS) mutation testing and impact on survival Journal of Clinical Oncology, 2018, 36, 6023-6023.	0.8	3
134	The synergy of germline C634Y and V292M RET mutations in a northern Chinese family with multiple endocrine neoplasia type 2A. Journal of Cellular and Molecular Medicine, 2020, 24, 13163-13170.	1.6	3
135	Outcomes after definitive surgery for mandibular osteoradionecrosis. Head and Neck, 2022, 44, 1313-1323.	0.9	3
136	Occlusion of the internal jugular vein in differentiated thyroid carcinoma: Causes and diagnosis. European Journal of Surgical Oncology, 2021, 47, 1552-1557.	0.5	2
137	RAS-mutated sporadic medullary thyroid cancer: A single-center experience Journal of Clinical Oncology, 2020, 38, 6584-6584.	0.8	2
138	Lateral Neck Dissection for Papillary Thyroid Cancer. VideoEndocrinology, 2020, 7, .	0.1	1
139	Genomic landscape of FNAs positive for medullary thyroid cancer (MTC) and potential impact on systemic therapy Journal of Clinical Oncology, 2019, 37, 6087-6087.	0.8	1
140	Locally Advanced Differentiated Thyroid Cancer. , 2017, , 395-417.		0
141	The Small World of Global Otolaryngology. Otolaryngologic Clinics of North America, 2018, 51, xix-xx.	0.5	0
142	Global Health in Otolaryngology. Otolaryngologic Clinics of North America, 2018, 51, i.	0.5	0
143	Lateral Neck Dissection: Indications and Technique. , 2021, , 379-385.e2.		0
144	Neoadjuvant Therapy for Anaplastic Thyroid Carcinoma. , 2021, , 81-88.		0

Neoadjuvant Therapy for Anaplastic Thyroid Carcinoma. , 2021, , 81-88. 144

#	Article	IF	CITATIONS
145	MON-LB097 The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier. Journal of the Endocrine Society, 2019, 3, .	0.1	Ο
146	Thyroid carcinoma metastasizing to the submandibular gland: Sonographic findings. Journal of Clinical Ultrasound, 2020, 48, 227-230.	0.4	0
147	Abstract 1662:In vivodrug response evaluation in anaplastic thyroid cancer patient-derived tumor xenografts following high-throughput screening. , 2020, , .		Ο
148	MON-LB015 Sporadic MTC in Children: Characterization of a Rare Disease. Journal of the Endocrine Society, 2020, 4, .	0.1	0
149	Improved laryngeal function after neoadjuvant therapy for advanced thyroid cancer: A potential outcome of interest for future clinical trials Journal of Clinical Oncology, 2022, 40, e18030-e18030.	0.8	0